169 F. Supp. 3d 1204
D.N.M.2016Background
- Plaintiff New Mexico Oncology and Hematology Consultants, Ltd. (NMOHC) is a freestanding comprehensive oncology provider in Albuquerque and surrounding areas; Defendants are Presbyterian Healthcare Services (largest NM hospital system) and Presbyterian Network, Inc. (PHP), an insurer affiliate.
- NMOHC previously sued alleging antitrust and RICO claims; the court earlier sustained monopolization claims based on Defendants’ alleged monopoly in the private health insurance market.
- In the Third Amended Complaint (TAC) NMOHC added new monopolization/attempted monopolization claims alleging Defendants monopolized an inpatient hospital services market and used that power to injure NMOHC’s comprehensive oncology business.
- NMOHC alleges exclusionary acts (intimidating physicians, discouraging/interfering with referrals, offering financial incentives to withhold referrals, and altering referral-processing systems) but does not specify that those acts were confined to inpatient hospital services.
- Defendants moved to dismiss the new inpatient-hospital-market monopolization claims for failure to state a claim and for lack of antitrust standing/antitrust injury.
- The court granted the motion, holding NMOHC lacks antitrust standing as to the inpatient hospital services market because it failed to plead a causal antitrust injury tied to monopoly power in that market; the previously-allowed insurance-market claims remain unaffected.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Standing to sue for monopolization of inpatient hospital services | NMOHC is a perceived competitor (competes with Presbyterian in oncology) and thus may assert harm caused by Defendants’ inpatient-market monopoly | NMOHC lacks standing because it does not participate in the inpatient hospital market and suffered no antitrust injury from that market | Court: NMOHC is a perceived competitor but lacks antitrust injury tied to inpatient market; thus no standing for these claims |
| Causal link between alleged exclusionary conduct and inpatient-market monopoly | Exclusionary acts (physician intimidation, referral interference, incentives, IT changes) flowed from Defendants’ inpatient-market power and harmed NMOHC’s oncology business | The alleged conduct relates to inpatient and outpatient contexts and is not tied to leveraging inpatient-bed dominance; no allegations show use of inpatient-market power to cause the harm | Court: Allegations fail to show the exclusionary conduct was caused by or employed inpatient-market monopoly power; causal connection insufficient |
| Market definition and market power pleading | NMOHC defines inpatient hospital services broadly but pleads Defendants’ market share using staffed beds and inpatient discharges | Defendants argue the complaint does not plausibly allege monopoly power or exclusionary conduct within the inpatient market | Court: Even accepting facts, the market must be confined to inpatient admissions (per pleaded metrics) and the complaint does not tie exclusionary acts to that market power; therefore insufficient to show antitrust injury |
| Relation to previously-allowed insurance-market monopolization claims | NMOHC contends inpatient-market theory is an alternative path to show monopolization harms | Defendants argue the inpatient-market claims are distinct and deficient | Court: Dismissed inpatient-market claims for lack of standing, but explicitly preserved earlier claims based on alleged monopoly in the private health insurance market |
Key Cases Cited
- Twombly v. Bell Atlantic Corp., 550 U.S. 544 (plausibility standard for pleadings)
- Ashcroft v. Iqbal, 556 U.S. 662 (no mere conclusory allegations; plausibility required)
- Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc., 429 U.S. 477 (definition of antitrust injury)
- Associated General Contractors v. Carpenters, 459 U.S. 519 (factors for antitrust standing analysis)
- Reazin v. Blue Cross & Blue Shield, Inc., 899 F.2d 951 (Tenth Circuit discussion of perceived competitor and antitrust standing)